{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:59:58Z","timestamp":1781715598457,"version":"3.54.5"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bethune Charitable Foundation Advanced Solid Tumor Research Funding"},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-A-060"],"award-info":[{"award-number":["2025-PUMCH-A-060"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoplastic fever (NF) severely impairs quality of life and often limits antitumor therapy, yet effective treatment remains lacking. Given the central role of interleukin-6 (IL-6), we evaluated tocilizumab for NF management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed NF cases at 3 Chinese hospitals (2019-2023). Patients who received tocilizumab and had evaluable follow-up data were included in analyses of fever resolution, afebrile duration, Karnofsky Performance Status, inflammatory markers, antitumor outcomes, and adverse events (AEs). In patients with sequential exposure to non-steroidal anti-inflammatory drugs (NSAIDs) and tocilizumab, changes in inflammatory markers after each treatment were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-five patients were identified (median age 65). All had elevated CRP and IL-6. Among 22 treated with tocilizumab, all achieved fever resolution within 24\u2009hours, sustained for \u22652\u2009weeks, with significant reductions in CRP (mean, 95.7-19.0\u2009mg\/L) and other inflammatory markers. Median afebrile duration was 3\u2009weeks, extended to 4\u2009weeks with re-treatment. Systemic therapy was subsequently administered in patients with poor baseline performance, who achieved an objective response rate of 50%, a median progression-free survival of 11.6\u2009months, and an overall survival of 21.3\u2009months. AEs occurred in 81.8% (grade \u22653, 31.8%) but were manageable. Compared with NSAIDs, tocilizumab uniquely improved anemia and inflammatory control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tocilizumab provided rapid and durable fever resolution with systemic anti-inflammatory effects, accompanied by functional and hematologic improvement. These findings suggest IL-6 blockade as a promising therapeutic option for NF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag192","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:49:57Z","timestamp":1778845797000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0646-4871","authenticated-orcid":false,"given":"Yu","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5058-5658","authenticated-orcid":false,"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7630-819X","authenticated-orcid":false,"given":"Yang","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8811-4310","authenticated-orcid":false,"given":"Qiqi","family":"Dou","sequence":"additional","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine Xinglin College , Shengyang, 110135,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-2280","authenticated-orcid":false,"given":"Hanping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-3045","authenticated-orcid":false,"given":"Xiaoyan","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2133-4323","authenticated-orcid":false,"given":"Xuefei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beijing Water Conservancy Hospital , Beijing, 100036,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Emergency General Hospital , Beijing, 100028,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-1280","authenticated-orcid":false,"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1685-1515","authenticated-orcid":false,"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8101-672X","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, 100730,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026061711574404200_oyag192-B1","first-page":"870","article-title":"Neoplastic fever: a neglected paraneoplastic syndrome","volume":"13","author":"Zell","year":"2005","journal-title":"Support Care Cancer"},{"key":"2026061711574404200_oyag192-B2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/026921639601000306","article-title":"Neoplastic fever","volume":"10","author":"Johnson","year":"1996","journal-title":"Palliat Med"},{"key":"2026061711574404200_oyag192-B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJMp1212725","article-title":"Fever of unknown origin or fever of too many origins?","volume":"368","author":"Horowitz","year":"2013","journal-title":"N Engl J Med"},{"key":"2026061711574404200_oyag192-B4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00520-005-0898-0","article-title":"Causes of fever in cancer patients (prospective study over 477 episodes)","volume":"14","author":"Toussaint","year":"2006","journal-title":"Support Care Cancer"},{"key":"2026061711574404200_oyag192-B5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s13224-023-01744-0","article-title":"Neoplastic fever: a rare differential of intractable fever","volume":"73","author":"Agrawal","year":"2023","journal-title":"J Obstet Gynaecol India"},{"key":"2026061711574404200_oyag192-B6","doi-asserted-by":"publisher","first-page":"e15840","DOI":"10.1097\/MD.0000000000015840","article-title":"Naproxen for the treatment of neoplastic fever: a PRISMA-compliant systematic review and meta-analysis","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2026061711574404200_oyag192-B7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0885-3924(88)90159-5","article-title":"Antipyretic effect of naproxen and corticosteroids on neoplastic fever","volume":"3","author":"Chang","year":"1988","journal-title":"J Pain Symptom Manage"},{"key":"2026061711574404200_oyag192-B8","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1016\/j.amjmed.2022.03.014","article-title":"Tumor fever due to metastatic esophageal squamous cell carcinoma","volume":"135","author":"Isaza","year":"2022","journal-title":"Am J Med"},{"key":"2026061711574404200_oyag192-B9","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026061711574404200_oyag192-B10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting interleukin-6 signaling in clinic","volume":"50","author":"Kang","year":"2019","journal-title":"Immunity"},{"key":"2026061711574404200_oyag192-B11","doi-asserted-by":"publisher","first-page":"e007530","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026061711574404200_oyag192-B12","doi-asserted-by":"publisher","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","article-title":"Interleukin (IL-6) immunotherapy","volume":"10","author":"Tanaka","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026061711574404200_oyag192-B13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R","article-title":"Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma","volume":"72","author":"Blay","year":"1997","journal-title":"Int J Cancer"},{"key":"2026061711574404200_oyag192-B14","doi-asserted-by":"publisher","first-page":"e20190450","DOI":"10.1084\/jem.20190450","article-title":"Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia","volume":"218","author":"Rupert","year":"2021","journal-title":"J Exp Med"},{"key":"2026061711574404200_oyag192-B15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"2026061711574404200_oyag192-B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell"},{"key":"2026061711574404200_oyag192-B17","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.7150\/thno.92922","article-title":"Immunotherapeutic IL-6R and targeting the MCT-1\/IL-6\/CXCL7\/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer","volume":"14","author":"Haq","year":"2024","journal-title":"Theranostics"},{"key":"2026061711574404200_oyag192-B18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026061711574404200_oyag192-B19","doi-asserted-by":"publisher","first-page":"e0181125","DOI":"10.1371\/journal.pone.0181125","article-title":"High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer","volume":"12","author":"Silva","year":"2017","journal-title":"PLoS One"},{"key":"2026061711574404200_oyag192-B20","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biol"},{"key":"2026061711574404200_oyag192-B21","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","article-title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy","volume":"12","author":"Bent","year":"2021","journal-title":"Nat Commun"},{"key":"2026061711574404200_oyag192-B22","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.3390\/cancers14235985","article-title":"High serum levels of IL-6 predict poor responses in patients treated with pembrolizumab plus axitinib for advanced renal cell carcinoma","volume":"14","author":"Sang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026061711574404200_oyag192-B23","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/jcsm.13638","article-title":"Tocilizumab for advanced non-small-cell lung cancer with concomitant cachexia: an observational study","volume":"15","author":"Du","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026061711574404200_oyag192-B24","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1200\/JCO-25-01631","article-title":"Randomized phase II study of Nab-Paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in advanced pancreatic cancer: survival and cachexia","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026061711574404200_oyag192-B25","doi-asserted-by":"publisher","first-page":"104088","DOI":"10.1016\/j.esmoop.2024.104088","article-title":"Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers","volume":"10","author":"Blay","year":"2025","journal-title":"ESMO Open"},{"key":"2026061711574404200_oyag192-B26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026061711574404200_oyag192-B27","doi-asserted-by":"publisher","first-page":"e000756","DOI":"10.1136\/esmoopen-2020-000756","article-title":"Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma","volume":"5","author":"Eberst","year":"2020","journal-title":"ESMO Open"},{"key":"2026061711574404200_oyag192-B28","doi-asserted-by":"publisher","first-page":"5532258","DOI":"10.1155\/2021\/5532258","article-title":"Tocilizumab controls paraneoplastic inflammatory syndrome but does not suppress tumor growth of angiomatoid fibrous histiocytoma","volume":"2021","author":"Sabe","year":"2021","journal-title":"Case Rep Oncol Med"},{"key":"2026061711574404200_oyag192-B29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00520-002-0432-6","article-title":"Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever","volume":"11","author":"Kathula","year":"2003","journal-title":"Support Care Cancer"},{"key":"2026061711574404200_oyag192-B30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1006\/gyno.1995.1041","article-title":"The effect of naproxen on fever in patients with advanced gynecologic malignancies","volume":"56","author":"Economos","year":"1995","journal-title":"Gynecol Oncol"},{"key":"2026061711574404200_oyag192-B31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2796.1990.tb00262.x","article-title":"A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever","volume":"228","author":"Tsavaris","year":"1990","journal-title":"J Intern Med"},{"key":"2026061711574404200_oyag192-B32","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J Exp Med"},{"key":"2026061711574404200_oyag192-B33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"2026061711574404200_oyag192-B34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"2026061711574404200_oyag192-B35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J Clin Invest"},{"key":"2026061711574404200_oyag192-B36","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061711574404200_oyag192-B37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13256-016-0833-7","article-title":"Secondary malignant giant cell tumor of bone due to malignant transformation 40 years after surgery without radiation therapy, presenting as fever of unknown origin: a case report","volume":"10","author":"Takesako","year":"2016","journal-title":"J Med Case Rep"},{"key":"2026061711574404200_oyag192-B38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.18433\/j3vw2f","article-title":"Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications","volume":"16","author":"Harirforoosh","year":"2013","journal-title":"J Pharm Pharm Sci"},{"key":"2026061711574404200_oyag192-B39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","article-title":"MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer","volume":"18","author":"Weng","year":"2019","journal-title":"Mol Cancer"},{"key":"2026061711574404200_oyag192-B40","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/gutjnl-2019-319200","article-title":"STAT3 activation through IL-6\/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis","volume":"69","author":"Heichler","year":"2020","journal-title":"Gut"},{"key":"2026061711574404200_oyag192-B41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.17219\/acem\/62120","article-title":"IL-6, IL-8 and TNF-\u03b1 levels correlate with disease stage in breast cancer patients","volume":"26","author":"Ma","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"2026061711574404200_oyag192-B42","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7]","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"2026061711574404200_oyag192-B43","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14397595.2017.1416924","article-title":"Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still\u2019s disease: a meta-analysis","volume":"28","author":"Ma","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2026061711574404200_oyag192-B44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cmi.2020.10.036","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis","volume":"27","author":"Tleyjeh","year":"2021","journal-title":"Clin Microbiol Infect"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag192\/68348351\/oyag192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag192\/68348351\/oyag192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag192\/68348351\/oyag192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:57:49Z","timestamp":1781711869000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag192\/8688480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag192","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,20]]},"article-number":"oyag192"}}